BR9908132A - Composição farmacêutica lìquida para administração oral - Google Patents

Composição farmacêutica lìquida para administração oral

Info

Publication number
BR9908132A
BR9908132A BR9908132-6A BR9908132A BR9908132A BR 9908132 A BR9908132 A BR 9908132A BR 9908132 A BR9908132 A BR 9908132A BR 9908132 A BR9908132 A BR 9908132A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
oral administration
agents
benzoxazinone
Prior art date
Application number
BR9908132-6A
Other languages
English (en)
Other versions
BRPI9908132B1 (pt
BRPI9908132B8 (pt
Inventor
Surendra M Bahal
Michael B Maurin
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9908132A publication Critical patent/BR9908132A/pt
Publication of BRPI9908132B1 publication Critical patent/BRPI9908132B1/pt
Publication of BRPI9908132B8 publication Critical patent/BRPI9908132B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"COMPOSIçãO FARMACêUTICA LìQUIDA PARA ADMINISTRAçãO ORAL"<D> A presente invenção trata de uma composição farmacêutica líquida oral palatável de compostos de benzoxazinona utilizáveis como inibidores da transcriptase reversa de HIV, a qual compreende o ingrediente ativo de benzoxazinona em um veículo líquido que compreende triglicerídios de ácidos graxos de cadeias médias. Outros agentes de formulação, tais como agentes adoçantes, agentes de suspensão de lecitina, etc., podem ser opcionalmente adicionados.
BRPI9908132A 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral BRPI9908132B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7488198P 1998-02-17 1998-02-17
PCT/US1999/003318 WO1999040921A2 (en) 1998-02-17 1999-02-17 Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BR9908132A true BR9908132A (pt) 2000-12-05
BRPI9908132B1 BRPI9908132B1 (pt) 2015-07-14
BRPI9908132B8 BRPI9908132B8 (pt) 2016-11-16

Family

ID=22122226

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9908132A BRPI9908132B8 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral
BRPI9908132A BRPI9908132C1 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9908132A BRPI9908132C1 (pt) 1998-02-17 1999-02-17 composição farmacêutica líquida para administração oral

Country Status (18)

Country Link
US (1) US6235733B1 (pt)
EP (1) EP1054674B1 (pt)
JP (1) JP2002502878A (pt)
CN (1) CN1170541C (pt)
AR (1) AR018092A1 (pt)
AT (1) ATE345802T1 (pt)
AU (1) AU745008C (pt)
BR (2) BRPI9908132B8 (pt)
CA (1) CA2319609C (pt)
DE (1) DE69934097T2 (pt)
ES (1) ES2277429T3 (pt)
HR (1) HRP990049A2 (pt)
IL (1) IL137763A0 (pt)
MY (1) MY139034A (pt)
NZ (1) NZ506579A (pt)
TW (1) TW528596B (pt)
WO (1) WO1999040921A2 (pt)
ZA (1) ZA99981B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3525792A4 (en) * 2016-10-11 2020-04-22 Aucta Pharmaceuticals POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5494936A (en) * 1992-04-27 1996-02-27 Vyrex Corporation Delivery formulation for probucol
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en) 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
WO1997040833A1 (en) 1996-05-02 1997-11-06 Merck & Co., Inc. Hiv protease inhibitors useful for the treatment of aids
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same

Also Published As

Publication number Publication date
HK1030749A1 (en) 2001-05-18
ES2277429T3 (es) 2007-07-01
DE69934097D1 (de) 2007-01-04
AU745008B2 (en) 2002-03-07
CN1170541C (zh) 2004-10-13
WO1999040921A2 (en) 1999-08-19
AU2682799A (en) 1999-08-30
HRP990049A2 (en) 1999-12-31
DE69934097T2 (de) 2007-06-28
AR018092A1 (es) 2001-10-31
AU745008C (en) 2003-03-27
JP2002502878A (ja) 2002-01-29
BRPI9908132C1 (pt) 2021-05-25
WO1999040921A3 (en) 1999-11-04
EP1054674A2 (en) 2000-11-29
BRPI9908132B1 (pt) 2015-07-14
BRPI9908132B8 (pt) 2016-11-16
ZA99981B (en) 2000-08-08
NZ506579A (en) 2002-11-26
US6235733B1 (en) 2001-05-22
CA2319609C (en) 2007-09-18
IL137763A0 (en) 2001-10-31
CN1291098A (zh) 2001-04-11
CA2319609A1 (en) 1999-08-19
MY139034A (en) 2009-08-28
ATE345802T1 (de) 2006-12-15
TW528596B (en) 2003-04-21
EP1054674B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
HRP20010615B1 (hr) Farmaceutski pripravak koji sadržava inhibitore protonske pumpe
BR9907647A (pt) Composições contendo composto orgânicos
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
AR007040A1 (es) Compuestos de eritromicina 6-0-sustituida, composiciones farmaceuticas, uso de dichos compuestos para preparar medicamentos y procedimiento para supreparacion
TR200003108T2 (tr) İlaç kompozisyonları
BR0116380A (pt) Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica
BR0112417A (pt) Composições farmacêuticas contendo composto dds
NO20000310L (no) Farmasøytiske sammensetninger som inneholder vitamin D og kalsium, deres fremstilling og terapeutisk anvendelse
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
PA8496701A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo [2.2.2] oct- 3 - ilamina y sus composiciones farmaceuticas
BRPI9908132C1 (pt) composição farmacêutica líquida para administração oral
ES2158309T3 (es) Fenilamidinas sustituidas, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO ESTABELECIDO PELOS ARTIGOS 8O E 13 DA LPI (LEI 9729/96)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI NO 2323 DE 14/07/2015, QUANTO AO ENDERECO DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17/02/2019